Insulin analogues with increased mitogenic potency - Are they safe?

Hormone and Metabolic Research

Volumn 40, Issue 6, 2008, Pages 431-433

  Hansen, B F ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN DERIVATIVE; INSULIN GLARGINE;

CARCINOGENICITY; CELL DIVISION; HUMAN; IN VITRO STUDY; METABOLISM; MITOGENESIS; MOLECULE; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK; TOXICOLOGY;

ANIMALS; CARCINOGENICITY TESTS; CELL DIVISION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MITOGENS; MUTAGENICITY TESTS; RECEPTOR, IGF TYPE 1; TUMOR CELLS, CULTURED;

EID: 47049110494     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1062740     Document Type: Note

References (14)

1. Oiknine R, Bembaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs 2005; 65: 325-340
2. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85-96
3. Drejer K. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 1992; 8: 259-286
4. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005
5. Hansen BF, Danielsen GM, Drejer K, Sorensen AR, Wiberg FC, Klein HH et al. Sustained signaling from the insulin-receptor after stimulation with insulin analogs exhibiting increased mitogenic potency. Biochem J 1996; 315: 271-279
6. Liefvendahl E, Arnqvist HJ. Mitogenic Effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-1. Horm Metab Res 2008 April 07, [Epub ahead of print]
7. Slieker LJ, Brooke GS, Dimarchi RD, Flora DB, Green LK, Hoffmann JA et al. Modifications in the b10-region and b26-30-region of the b-chain of human insulin alter affinity for the human igf-i-receptor more than for the insulin-receptor. Diabetologia 1997; 40: S54-S61
8. Staiger K, Hennige AM, Staiger H, Haering HU, Kellerer M. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Hormone Met 2007; 39: 65-67
9. Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 2002; 21: 171-179
10. Kuerzel GU, Shukla U, Scholtz HE, Pretorius SG, Wessels DH, Venter C et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 2003; 19: 34-40
11. Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Haring HU. The long-acting human insulin analog hoe-901 - characteristics of insulin signaling in comparison to asp(b10) and regular insulin. Hormone Met 1998; 30: 123-129
12. Bahr M, Kolter T, Seipke G, Eckel J. Growth-promoting and metabolic-activity of the human insulin analog [gly(a21),arg(b31),arg(b32)] insulin (hoe-901) in muscle-cells. Eur J Pharmacol 1997; 320: 259-265
13. Kohn WD, Micanovic R, Myers SL, Vick AM, Kahl SD, Zhang LS et al. pi-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity. Peptides 2007; 28: 935-948
14. Ciaraldi TP, Carter L, Seipke G, Mudaliar S, Henry RR. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: Comparisons to insulin and IGF-I. J Clin Endocrinol Metab 2001; 86: 5838-5847